STOCK TITAN

Sandoz Group AG - SDZNY STOCK NEWS

Welcome to our dedicated page for Sandoz Group news (Ticker: SDZNY), a resource for investors and traders seeking the latest updates and insights on Sandoz Group stock.

Sandoz Group AG S/ADR (SDZNY) is a global leader in generic and biosimilar medicines, providing affordable and high-quality treatments to patients worldwide. With a diverse portfolio of over 1500 products, Sandoz addresses a wide range of diseases from the common cold to cancer. Their recent achievements include the launch of new biosimilar products like Pyzchiva® and the expansion of production facilities to meet growing demand.

Rhea-AI Summary

The FDA has approved Pyzchiva® (ustekinumab-ttwe), a biosimilar developed by Samsung Bioepis, for all indications of its reference medicine, Stelara®. Pyzchiva® is set to be commercialized by Sandoz in the US starting February 2025, following a settlement with Janssen Biotech. This biosimilar will be available in various forms, including pre-filled syringes and vials for subcutaneous and intravenous administration. FDA's provisional determination also makes Pyzchiva® interchangeable with Stelara®. This approval is a significant milestone for Sandoz, enhancing its immunology portfolio and market position. The medication is approved for treating multiple conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The approval is based on robust clinical studies demonstrating equivalent efficacy and safety compared to its reference medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
-
Rhea-AI Summary

Sandoz has secured European Commission approval for Wyost® and Jubbonti®, the first biosimilars of denosumab in Europe. Wyost® is approved for cancer-related bone disease, while Jubbonti® is for osteoporosis. These approvals, based on a robust development program, mark a significant growth milestone for Sandoz.

Wyost® and Jubbonti® will launch in November 2025. The approvals aim to increase access to essential treatments and align with Sandoz's strategy to provide sustainable healthcare solutions. Cancer and osteoporosis are significant health burdens, with cancer-related bone diseases affecting many patients and osteoporosis increasing fracture risks in the aging population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
Rhea-AI Summary

Sandoz reported strong first quarter 2024 sales with net sales of USD 2.5 billion, up 6% in constant currencies. Biosimilar business grew by 21%, all regions contributed to growth. Acquisition of CIMERLI® completed in March 2024. Generics sales remained steady. Full-year net sales guidance of mid-single digits in constant currencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
Rhea-AI Summary

Sandoz Group AG shareholders approved all proposals by the Board of Directors at the Annual General Meeting. Gilbert Ghostine was re-elected as Chairman, with Mathai Mammen, Graeme Pitkethly, and Michael Rechsteiner joining as new Board members. A dividend of CHF 0.45 per share was approved. The AGM also re-elected auditors and the independent proxy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
management
-
Rhea-AI Summary

Sandoz has reached an agreement with Amgen to resolve all patent litigation related to its US denosumab biosimilars, allowing for the launch of Jubbonti® and Wyost® on May 31, 2025, or earlier under certain conditions. These biosimilars are the first and only FDA-approved alternatives to Prolia® and Xgeva®. The settlement strengthens Sandoz's biosimilar portfolio and growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Summary
Sandoz receives European Commission approval for Pyzchiva® (ustekinumab), a key biosimilar therapy within gastroenterology, dermatology, and rheumatology, further strengthening their immunology portfolio. The approval is based on a robust development program confirming safety, efficacy, and quality match to the reference medicine. Sandoz remains committed to providing access to life-changing treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
Rhea-AI Summary
Sandoz invests EUR 50m in Kundl plant extension to increase antibiotic production capacity by 20% and double output levels, emphasizing commitment to serve more patients with critical antibiotics in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
-
Rhea-AI Summary
Sandoz reports strong fourth-quarter performance with net sales of USD 2.5 billion, up 10% in constant currencies. Full-year 2023 net sales reach USD 9.6 billion, up 7% in constant currencies. The company achieved growth across all regions, with biosimilars showing double-digit growth. Core EBITDA margin for 2023 was 18.1%, with a 2024 guidance of mid-single digit net sales growth and core EBITDA margin around 20%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Summary
Sandoz receives FDA approval for Wyost® and Jubbonti® as interchangeable biosimilars for Xgeva® and Prolia®, addressing various bone-related conditions. The approval is based on comprehensive clinical studies showing no significant differences from reference medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
Rhea-AI Summary
Sandoz announces Mathai Mammen and Michael Rechsteiner as nominees for the Board of Directors, Remco Steenbergen appointed as CFO. Colin Bond to retire. The proposed changes aim to enhance leadership and financial expertise within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
management

FAQ

What is Sandoz Group AG S/ADR known for?

Sandoz is known for being a global leader in generic and biosimilar medicines, offering affordable and high-quality treatments across a wide range of diseases.

What are some recent achievements of Sandoz Group AG S/ADR?

Recent achievements include the launch of new biosimilar products like Pyzchiva® and the expansion of production facilities to meet growing demand.

How many products are in Sandoz Group AG S/ADR's portfolio?

Sandoz has a diverse portfolio of over 1500 products that address diseases from the common cold to cancer.

What is the goal of Sandoz Group AG S/ADR?

Sandoz aims to pioneer access for patients by providing affordable and high-quality generic and biosimilar medicines worldwide.

Where is Sandoz Group AG S/ADR headquartered?

Sandoz is headquartered in Basel, Switzerland, with a history dating back to 1886.

What is the full-year 2024 guidance for Sandoz Group AG S/ADR?

The company expects net sales to grow mid-single digit in constant currencies versus the prior year, with a core EBITDA margin around 20%.

What recent biosimilar products were launched by Sandoz Group AG S/ADR?

Sandoz recently launched Pyzchiva® and CIMERLI®, expanding its biosimilar portfolio to provide safe and effective treatment options for patients.

Who is the CEO of Sandoz Group AG S/ADR?

Richard Saynor serves as the Chief Executive Officer of Sandoz, leading the company's growth and strategic initiatives.

When were the first FDA-approved denosumab biosimilars launched by Sandoz Group AG S/ADR?

The first and only FDA-approved denosumab biosimilars, Wyost® and Jubbonti®, were launched by Sandoz on March 5, 2024.

What recent acquisitions were made by Sandoz Group AG S/ADR?

Sandoz acquired CIMERLI® from Coherus BioSciences, Inc. to enhance its ophthalmic platform and strengthen its biosimilar portfolio.

What strategic milestone was achieved by Sandoz Group AG S/ADR in January 2024?

In January, Sandoz launched Tyruko®, the first biosimilar to treat relapsing remitting multiple sclerosis, improving access to essential therapies in Europe.

Sandoz Group AG

OTC:SDZNY

SDZNY Rankings

SDZNY Stock Data

15.56B
411.64M
0.4%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Basel